The VITILIGO THERAPEUTICS MARKET value is set to grow by USD 341.35 million, progressing at a CAGR of 4.5% from 2021 to 2026, as per the latest report by Technavio. The growing importance of the aesthetic appeal is notably driving the vitiligo therapeutics market growth, although factors such as poor patient adherence may impede the market growth.
The increasing importance of aesthetic appeal and the inclination of the population toward a better lifestyle have been fueling the market growth for vitiligo therapeutics despite the disease being non-life-threatening.
However, sometimes physicians do not provide individuals with adequate information about the drug’s chronic nature and anticipated side effects. In addition, the drugs prescribed by physicians may not be covered under insurance. These factors limit the use of vitiligo therapeutics among individuals.
Browse Summary of the VITILIGO THERAPEUTICS MARKET Research Report to Learn MoreVitiligo Therapeutics Market 2022-2026: Segmentation
- Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
32% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for vitiligo therapeutics in North America. Market growth in this region will be slower than the growth of the market in regions.
- Route of administration
- Topical
- Oral
- Others
The vitiligo therapeutics market share growth by the topical segment will be significant during the forecast period. This topical drugs segment is expected to grow during the forecast period as most of the pipeline drugs that are being developed by the big pharmaceutical players are topical-based medications.
Download VITILIGO THERAPEUTICS MARKET Sample Report to Gain Further InsightsVitiligo Therapeutics Market 2022-2026: Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our report covers the following areas:
- Vitiligo Therapeutics Market size
- Vitiligo Therapeutics Market trends
- Vitiligo Therapeutics Market analysis
Vitiligo Therapeutics Market 2022-2026: Vendor Analysis
- Alkem Laboratories Ltd.
- AmerisourceBergen Corp.
- Astellas Pharma Inc.
- Bausch Health Companies Inc.
- Baxter International Inc.
- Biocon Ltd.
- Canixa Life Sciences
- Concord Biotech Ltd.
- Dr. Reddys Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd.
- La Pristine Bioceuticals Pvt. Ltd.
- LEO Pharma AS
- Mallinckrodt Plc
- Panacea Biotec Ltd.
- Pfizer Inc.
- Puneet Laboratories Pvt. Ltd.
- Sandoz International GmbH
- Strides Pharma Science Ltd
- Teva Pharmaceutical Industries Ltd.
- Veloxis Pharmaceuticals AS
- Viatris Inc.
The vitiligo therapeutics market is fragmented and the vendors are deploying growth strategies such as focusing on increasing their presence and broadening their product portfolio through M&A to compete in the market.
View VITILIGO THERAPEUTICS MARKET Sample Report (Including Graphs & Tables)Vitiligo Therapeutics Market 2022-2026: Key Highlights
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist vitiligo therapeutics market growth during the next five years
- Estimation of the vitiligo therapeutics market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the vitiligo therapeutics market
- Analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of vitiligo therapeutics market vendors
Related Reports:
Browse Summary of the SARCOMA THERAPEUTICS MARKET Report by Type and Geography – Forecast and Analysis 2022-2026: The market value is set to grow by USD 1.18 billion, progressing at a CAGR of 9% from 2021 to 2026, as per the latest report by Technavio. Furthermore, this report extensively covers sarcoma therapeutics market segmentation by type (soft tissue sarcoma and osteosarcoma) and geography (North America, Europe, APAC, and Rest of the World (ROW)).
Browse Summary of the HAIRY CELL LEUKEMIA THERAPEUTICS MARKET Report by Product and Geography – Forecast and Analysis 2022-2026: The market value is set to grow by USD 177.85 million, progressing at a CAGR of 6.7% from 2021 to 2026, as per the latest report by Technavio. The hairy cell leukemia therapeutics market report also offers information on several market vendors, including AbbVie Inc., Amgen Inc., Astex Pharmaceuticals Inc., and more.
| Vitiligo Therapeutics Market Scope | |
| Report Coverage | Details |
| Page number | 120 |
| Base year | 2021 |
| Forecast period | 2022-2026 |
| Growth momentum & CAGR | Accelerate at a CAGR of 4.5% |
| Market growth 2022-2026 | $ 341.35 million |
| Market structure | Fragmented |
| YoY growth (%) | 3.5 |
| Regional analysis | North America, Europe, Asia, and Rest of World (ROW) |
| Performing market contribution | North America at 32% |
| Key consumer countries | US, Canada, China, Germany, and UK |
| Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
| Companies profiled | Alkem Laboratories Ltd., AmerisourceBergen Corp., Astellas Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Biocon Ltd., Canixa Life Sciences, Concord Biotech Ltd., Dr. Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., La Pristine Bioceuticals Pvt. Ltd., LEO Pharma AS, Mallinckrodt Plc, Panacea Biotec Ltd., Pfizer Inc., Puneet Laboratories Pvt. Ltd., Sandoz International GmbH, Strides Pharma Science Ltd, Teva Pharmaceutical Industries Ltd., Veloxis Pharmaceuticals AS, and Viatris Inc. |
| Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
| Customization preview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse for Technavio “HEALTH CARE MARKET” Research ReportsTable of Contents:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis – Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition – Five forces 2021 and 2026
5 Market Segmentation by Route of Administration
- 5.1 Market segments
- Exhibit 24: Chart on Route of Administration – Market share 2021-2026 (%)
- Exhibit 25: Data Table on Route of Administration – Market share 2021-2026 (%)
- 5.2 Comparison by Route of Administration
- Exhibit 26: Chart on Comparison by Route of Administration
- Exhibit 27: Data Table on Comparison by Route of Administration
- 5.3 Topical – Market size and forecast 2021-2026
- Exhibit 28: Chart on Topical – Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Topical – Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Topical – Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Topical – Year-over-year growth 2021-2026 (%)
- 5.4 Oral – Market size and forecast 2021-2026
- Exhibit 32: Chart on Oral – Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Oral – Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Oral – Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Oral – Year-over-year growth 2021-2026 (%)
- 5.5 Others – Market size and forecast 2021-2026
- Exhibit 36: Chart on Others – Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Others – Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Others – Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Others – Year-over-year growth 2021-2026 (%)
- 5.6 Market opportunity by Route of Administration
- Exhibit 40: Market opportunity by Route of Administration ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 42: Chart on Market share by geography 2021-2026 (%)
- Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 44: Chart on Geographic comparison
- Exhibit 45: Data Table on Geographic comparison
- 7.3 North America – Market size and forecast 2021-2026
- Exhibit 46: Chart on North America – Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on North America – Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on North America – Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on North America – Year-over-year growth 2021-2026 (%)
- 7.4 Europe – Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe – Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe – Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe – Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe – Year-over-year growth 2021-2026 (%)
- 7.5 Asia – Market size and forecast 2021-2026
- Exhibit 54: Chart on Asia – Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Asia – Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Asia – Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Asia – Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) – Market size and forecast 2021-2026
- Exhibit 58: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
- 7.7 US – Market size and forecast 2021-2026
- Exhibit 62: Chart on US – Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on US – Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on US – Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on US – Year-over-year growth 2021-2026 (%)
- 7.8 China – Market size and forecast 2021-2026
- Exhibit 66: Chart on China – Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on China – Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on China – Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on China – Year-over-year growth 2021-2026 (%)
- 7.9 Germany – Market size and forecast 2021-2026
- Exhibit 70: Chart on Germany – Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on Germany – Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on Germany – Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Germany – Year-over-year growth 2021-2026 (%)
- 7.10 Canada – Market size and forecast 2021-2026
- Exhibit 74: Chart on Canada – Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Canada – Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Canada – Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Canada – Year-over-year growth 2021-2026 (%)
- 7.11 UK – Market size and forecast 2021-2026
- Exhibit 78: Chart on UK – Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on UK – Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on UK – Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on UK – Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 82: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 83: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 85: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 86: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 87: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 88: Matrix on vendor position and classification
- 10.3 Alkem Laboratories Ltd.
- Exhibit 89: Alkem Laboratories Ltd. – Overview
- Exhibit 90: Alkem Laboratories Ltd. – Business segments
- Exhibit 91: Alkem Laboratories Ltd. – Key news
- Exhibit 92: Alkem Laboratories Ltd. – Key offerings
- Exhibit 93: Alkem Laboratories Ltd. – Segment focus
- 10.4 Astellas Pharma Inc.
- Exhibit 94: Astellas Pharma Inc. – Overview
- Exhibit 95: Astellas Pharma Inc. – Product / Service
- Exhibit 96: Astellas Pharma Inc. – Key news
- Exhibit 97: Astellas Pharma Inc. – Key offerings
- 10.5 Bausch Health Companies Inc.
- Exhibit 98: Bausch Health Companies Inc. – Overview
- Exhibit 99: Bausch Health Companies Inc. – Business segments
- Exhibit 100: Bausch Health Companies Inc. – Key news
- Exhibit 101: Bausch Health Companies Inc. – Key offerings
- Exhibit 102: Bausch Health Companies Inc. – Segment focus
- 10.6 Baxter International Inc.
- Exhibit 103: Baxter International Inc. – Overview
- Exhibit 104: Baxter International Inc. – Business segments
- Exhibit 105: Baxter International Inc. – Key news
- Exhibit 106: Baxter International Inc. – Key offerings
- Exhibit 107: Baxter International Inc. – Segment focus
- 10.7 La Pristine Bioceuticals Pvt. Ltd.
- Exhibit 108: La Pristine Bioceuticals Pvt. Ltd. – Overview
- Exhibit 109: La Pristine Bioceuticals Pvt. Ltd. – Product / Service
- Exhibit 110: La Pristine Bioceuticals Pvt. Ltd. – Key offerings
- 10.8 Mallinckrodt Plc
- Exhibit 111: Mallinckrodt Plc – Overview
- Exhibit 112: Mallinckrodt Plc – Business segments
- Exhibit 113: Mallinckrodt Plc – Key news
- Exhibit 114: Mallinckrodt Plc – Key offerings
- Exhibit 115: Mallinckrodt Plc – Segment focus
- 10.9 Pfizer Inc.
- Exhibit 116: Pfizer Inc. – Overview
- Exhibit 117: Pfizer Inc. – Product / Service
- Exhibit 118: Pfizer Inc. – Key news
- Exhibit 119: Pfizer Inc. – Key offerings
- 10.10 Puneet Laboratories Pvt. Ltd.
- Exhibit 120: Puneet Laboratories Pvt. Ltd. – Overview
- Exhibit 121: Puneet Laboratories Pvt. Ltd. – Product / Service
- Exhibit 122: Puneet Laboratories Pvt. Ltd. – Key offerings
- 10.11 Teva Pharmaceutical Industries Ltd.
- Exhibit 123: Teva Pharmaceutical Industries Ltd. – Overview
- Exhibit 124: Teva Pharmaceutical Industries Ltd. – Business segments
- Exhibit 125: Teva Pharmaceutical Industries Ltd. – Key news
- Exhibit 126: Teva Pharmaceutical Industries Ltd. – Key offerings
- Exhibit 127: Teva Pharmaceutical Industries Ltd. – Segment focus
- 10.12 Viatris Inc.
- Exhibit 128: Viatris Inc. – Overview
- Exhibit 129: Viatris Inc. – Business segments
- Exhibit 130: Viatris Inc. – Key offerings
- Exhibit 131: Viatris Inc. – Segment focus
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 132: Inclusions checklist
- Exhibit 133: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 134: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 135: Research methodology
- Exhibit 136: Validation techniques employed for market sizing
- Exhibit 137: Information sources
- 11.5 List of abbreviations
- Exhibit 138: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio